ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO634

Gut Microbiome and Circulating Uremic Solutes in Patients with CKD

Session Information

Category: Bioengineering

  • 300 Bioengineering


  • Kim, Ji Eun, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Park, Ji In, Kangwon National University Hospital , Chuncheon-si,, Korea (the Republic of)
  • Cho, Hyunjeong, Chungbuk National University Hospital, Cheongju-si, Korea (the Republic of)
  • Yang, Seung Hee, Kidney Research Institute, Seoul National University, Seoul, Korea (the Republic of)
  • Lee, Jung Pyo, Seoul National University Boramae Medical Center, Seoul, Korea (the Republic of)
  • Kim, Dong Ki, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Lee, Hajeong, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Kim, Yon Su, Seoul National University College of Medicine, Seoul, Korea (the Republic of)

The relationship between gut microbiome and renal function through the gut-kidney axis comes into the spotlight. However, the changes of microbiome according to the stages of chronic kidney disease (CKD) and the dynamics of uremic toxins produced by gut microbiome are not yet known.


We prospectively enrolled 149 CKD patients with various renal functions and healthy kidney donors as controls. We collected fecal samples of all participants and the microbial profiling was performed by 16S rRNA sequencing. Also, we measured the level of 4 uremic toxins including p-cresyl sulfate, indoxyl sulfate, p-cresol glucuronide, and trimethylamine N-oxide in serum of all participants by Liquid chromatography–mass spectrometry.


Among the 149 participants, control, CKD stage 1 to 2, CKD stage 3 to 5 without dialysis, CKD stage 5 with dialysis were 46, 36, 32 and 35, respectively. The four uremic toxins were significantly increased with elevation of CKD stage. In microbial analysis with fecal samples, the abundances of genera Prevotella, Lachnospira and Dialister significantly decreased as the stage of CKD advanced. While, the abundances of genera Alistipes and Oscillibacter significantly increased as the stage of CKD advanced. Then, the uremic toxin-related microbiota was identified, and all four uremic toxins were associated with Alistipes, Oscillobacter and Lachnospira. These three genera showed significant correlations with both renal function and metabolite production.


We found that the composition of gut microbiota changed according to the stage of CKD. Especially, genera Alistipes, Oscillobacter and Lachnospira were correlated with levels of major uremic toxins. These results shows that gut microbiota might be a crucial factor for progression of CKD.